Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-12-17-Speech-2-213"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-12-17"^^xsd:date2
dcterms:Is Part Of	lp_eu:Question Time (Commission)2
dcterms:Language	"es"^^xsd:language2
lpv:document identification number	"en.20021217.7.2-213"2
lpv:hasSubsequent	lp_eu:2002-12-17-Speech-2-2142
lpv:speaker	lp:Alonso José Puerta2
lpv:spokenAs	unknown; Izquierda Unida (1999-07-20--2004-07-19)3 substitute; AFCO (2002-01-17--2004-07-19)3 member; Delegation for relations with the countries of Central America and Mexico (2002-02-07--2004-07-19)3 vice-president; Parliament's Bureau (2002-01-15--2004-07-19)3 member_of_the_bureau; EUL/NGL (1999-10-13--2004-07-19)3 member; Committee on Regional Policy, Transport and Tourism (2002-01-17--2004-07-19)3 vice-president; European Parliament (2002-01-15--2004-07-19)3
lpv:translated text	"Question No 38 by Mary Elizabeth Banotti (): In 1999 EU legislation was adopted with a view to encouraging research into the development of 'orphan' drugs for the treatment of rare diseases. It would now seem that unscrupulous drug companies are using the legislation to obtain exclusive rights to common medicines which are currently used in the treatment of rare disorders, therefore pushing up the cost of such drugs. Will the Commission undertake to inquire into the level of such abuse, and what measures will the Commission take to end such abuse and to ensure that the legislation is used for the purpose that it was intended, namely research for effective treatment of rare disorders?"@en1
lpv:unclassifiedMetadata	"President."1 "Subject: Abuse of EU research legislation covering orphan drugs"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph